BioStock: Evaxion Biotech to test EVX-01 in collaboration with Merck & Co.

Copenhagen-based Evaxion Biotech runs several projects based on its proprietary AI drug discovery platform. The main candidate EVX-01 is developed as a combination therapy with checkpoint inhibitors. A phase IIb trial is planned to start this winter, in which EVX-01 will be combined with blockbuster drug Keytruda after a recent collaboration agreement between Evaxion and Merck & Co. subsidiary MSD.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/10/evaxion-biotech-to-test-evx-01-in-collaboration-with-merck-co/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se